Trial Profile

A Multicenter, Open-label, Randomized, Phase 2 Study of NT-I7 in Combination With Nivolumab Versus Nivolumab Monotherapy in Subjects With Advanced or Metastatic Gastric or Gastro-Esophageal Junction or Esophageal Adenocarcinoma Who Progressed on or Intolerant to 2 or More Prior Lines of Systemic Therapy

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 20 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Aug 2023 This trial has been completed in Poland (Global end date: 26 May 2023).
25 Jul 2023 Status changed from active, no longer recruiting to discontinued.
10 Jul 2023 The trial has been discontinued in Spain (End Date: 26 May 2023), according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com